The Evidence Pack: How New Therapies Are Moving Celiac Disease Beyond the Gluten-Free Diet

For decades, the medical consensus on celiac disease has been as simple as it is unforgiving: stop eating gluten. For the estimated 1 in 100 people globally who carry the genetic autoimmune condition, the ingestion of wheat, barley, or rye triggers a severe immune response that attacks the small intestine.[1]

This immune cascade flattens the villi—the microscopic, finger-like projections responsible for absorbing nutrients—leading to malnutrition, chronic fatigue, osteoporosis, and an increased risk of certain lymphomas. The only prescribed treatment is a strict, lifelong gluten-free diet.[1][3]

But the reality of the gluten-free diet is far from perfect. Gluten is a ubiquitous structural protein used in everything from sauces and marinades to medications and cosmetics. Studies show that up to 70% of celiac patients who believe they are strictly adhering to the diet still suffer from accidental cross-contamination.[1][5]

This hidden exposure keeps their immune systems in a state of chronic, low-grade inflammation. For these patients, dining out, traveling, or attending social events requires a level of hyper-vigilance that exacts a heavy psychological toll.[3][4]

Now, the landscape of celiac care is undergoing a historic shift. As of 2026, a robust pipeline of pharmaceutical interventions has advanced into late-stage clinical trials. These therapies are not designed to be 'cures' that allow patients to consume a plate of conventional pasta. Instead, they are engineered as pharmaceutical safety nets—treatments meant to neutralize accidental cross-contamination and allow the gut to fully heal.[2][3][5]

The therapies currently leading the race fall into three distinct scientific approaches: gluten-degrading enzymes, immune-tolerizing nanoparticles, and transglutaminase 2 (TG2) inhibitors.[1][2]

The most advanced candidate is latiglutenase (also known as ZMGX003 or ALV003), an oral medication that patients would take alongside their meals. Developed by ZymagenX and Entero Therapeutics, latiglutenase is a mixture of two highly specific recombinant enzymes.[2][3]

Gluten proteins are notoriously difficult for the human body to digest because they are rich in the amino acid proline. Latiglutenase works by aggressively cleaving these proline-rich proteins in the highly acidic environment of the stomach, breaking the gluten down into harmless fragments before it ever reaches the immune sensors in the small intestine.[1][4]

The clinical evidence for latiglutenase is compelling. In a placebo-controlled Phase 2 trial, participants were subjected to a six-week 'gluten challenge,' consuming a controlled amount of gluten daily. The trial used the ratio of villus height to crypt depth—a direct measure of intestinal damage—as its primary endpoint.[2]

Latiglutenase proved statistically superior to the placebo, significantly reducing gluten-associated mucosal damage and improving patient symptoms. With the FDA having reviewed its clinical development plan, the drug is now advancing into pivotal Phase 3 trials, targeting a potential market entry by 2027.[2][4]

A completely different, 'back door' approach is being pioneered by Takeda and COUR Pharmaceuticals with a drug called TAK-101. Rather than trying to digest the gluten, TAK-101 aims to reprogram the patient's immune system to ignore it.[3]

TAK-101 utilizes a proprietary nanoparticle technology. A specific, highly reactive component of wheat is encapsulated inside a microscopic, biodegradable shell. Because it is hidden, the body's immune system does not immediately attack it.[3][5]

These nanoparticles travel to the spleen, a critical organ for immune regulation. There, the particles are consumed by specialized immune cells that interpret the encapsulated gluten as harmless cellular debris. This process induces 'immune tolerance,' effectively retraining the T-cells to stand down when they encounter gluten in the future.[3][4]

In Phase 2 dose-ranging studies, TAK-101 successfully mitigated gluten-induced immune activation in celiac patients adhering to a gluten-free diet, preventing the spike in gliadin-specific T-cells that typically follows exposure.[1][3]

A similar tolerizing approach is being developed by Anokion with KAN-101. Instead of the spleen, KAN-101 targets specific receptors in the liver to induce functional tolerance. The company has reported positive Phase 1b/2 results, showing the drug was well-tolerated and successfully blunted the immune response to gluten.[2][4]

The third major mechanism targets the gut's internal chemistry. When gluten enters the small intestine of a celiac patient, an enzyme called transglutaminase 2 (TG2) modifies the gluten fragments, making them exponentially more reactive and toxic to the immune system.[1][5]

TAK-227 (also known as ZED1227) is an oral small-molecule drug designed to inhibit this exact enzyme. By blocking TG2, the drug prevents the gluten from being modified, stopping the autoimmune cascade at its source.[2]

In a rigorous Phase 2 trial, patients taking TAK-227 underwent a daily 3-gram gluten challenge. Across all three tested dose levels, the drug demonstrated a significant protective effect against mucosal damage compared to the placebo.[1][2]

The FDA has set a high bar for these therapies, requiring proof of both histological healing—the physical repair of the villi—and symptom improvement. This dual endpoint has historically been difficult to meet, as gut healing often lags behind symptom relief.[4][5]

Despite the hurdles, the sheer volume of late-stage candidates suggests that the era of relying solely on dietary avoidance is coming to an end. For millions of patients, the approval of just one of these therapies would fundamentally transform their relationship with food, offering the first true biological shield against a world covered in crumbs.[3][5]